Pulmonx Reports Second Quarter 2026 Financial Results
Pulmonx reported Q2 2026 revenue of $22.8 million, down 5% year-over-year, with U.S. revenue declining 4% and international revenue falling 6% on a constant currency basis due to a lack of sales into China. Despite the revenue decline, the company achieved a record gross margin of 78% and reduced its net loss by 34% to $10.1 million, driven by a 16% decrease in operating expenses.
Key figures
- Revenue
- 22800000
- Guidance
- $90 million to $92 million
- Revenue Yoy
- -0.05
- Net loss
- 10100000
- Us revenue
- 14200000
- Gross margin
- 78%
- Operating expenses
- 26800000
- Adjusted ebitda loss
- 5100000
- Cash and equivalents
- 55800000
- International revenue
- 8600000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.